# Tirzepatide

> Dual GIP / GLP-1 receptor agonist with industry-leading weight-loss endpoints.

- Also known as: Mounjaro, Zepbound
- Class: Metabolic
- FDA approved: Yes
- Canonical page: https://americanpeptide.com/catalog/tirzepatide

## Overview

Tirzepatide is a 39-amino-acid synthetic peptide acting as a dual agonist at GIP and GLP-1 receptors. Approved by the FDA for type 2 diabetes (2022) and chronic weight management (2023).

Tirzepatide is a synthetic 39-amino-acid peptide that activates two incretin receptors at once — GIP (glucose-dependent insulinotropic polypeptide) and GLP-1. It carries a fatty-acid chain for albumin binding and once-weekly dosing, and is sometimes described as a "twincretin" for its dual mechanism.

Developed by Eli Lilly, it was approved for type 2 diabetes (Mounjaro, 2022) and chronic weight management (Zepbound, 2023). In placebo-controlled and head-to-head trials it produced some of the largest weight reductions reported for a pharmacologic agent, which has driven intense research interest in multi-receptor incretin design.

## Mechanism

Co-activation of GIP + GLP-1 receptors; complementary insulinotropic and satiety effects.

## Chemistry

| Property | Value |
| --- | --- |
| Molecular formula | C225H348N48O68 |
| Molecular weight | 4813.5 Da |
| CAS number | 2023788-19-2 |
| PubChem CID | [166567236](https://pubchem.ncbi.nlm.nih.gov/compound/166567236) |

## Research areas

Studied in: Type 2 diabetes, Obesity, Obstructive sleep apnea.

Guides on this site:

- [Weight Loss & Metabolic Health](https://americanpeptide.com/research-areas/weight-loss): Incretin and metabolic peptides studied for glycemic control and fat loss.
- [Sleep & Circadian Rhythm](https://americanpeptide.com/research-areas/sleep-circadian): Peptides studied for sleep architecture and circadian regulation.

## Key research

- Glycemic control — dual GIP/GLP-1 activation studied for insulin secretion and HbA1c reduction.
- Weight management — trials reported weight reductions exceeding those of single GLP-1 agonists.
- Obstructive sleep apnea — investigated as an endpoint in people with obesity.
- Cardiometabolic markers — examined for effects on lipids, blood pressure, and hepatic fat.
- Dual-agonism rationale — GIP is studied as complementary to GLP-1 for insulinotropic and satiety effects.

## Storage, handling & synthesis

**Storage.** Lyophilized: keep frozen and shielded from light. Reconstituted: store at 2–8 °C and use within weeks.

**Handling.** Swirl to dissolve rather than shaking; keep away from heat and minimize repeated freeze–thaw.

**Synthesis.** At 39 residues with a fatty-acid chain and a dual-receptor design, tirzepatide is a long, demanding synthesis — more coupling cycles mean more deletion and truncation impurities for purification to remove. Its length is exactly why a credible purity figure and an actual chromatogram matter here.

## FAQs

### What is tirzepatide?

Tirzepatide is a dual GIP/GLP-1 receptor agonist approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound).

### How is tirzepatide different from semaglutide?

Semaglutide activates the GLP-1 receptor alone; tirzepatide activates both GIP and GLP-1 receptors, a dual mechanism studied for greater metabolic effect.

### What does "twincretin" mean?

It is an informal term for a peptide that engages two incretin pathways — here GIP and GLP-1 — within a single molecule.

### Is tirzepatide FDA approved?

Yes, for type 2 diabetes and chronic weight management under the brand names Mounjaro and Zepbound. This page is a research and educational reference.

## Latest research

Recent trials and publications mentioning Tirzepatide, pulled automatically from ClinicalTrials.gov and PubMed (unfiltered search results, refreshed daily).

### Recent trials

- [Functional, Cognitive, and Behavioral Correlates of Resistance Training During Tirzepatide-Induced Weight Loss](https://clinicaltrials.gov/study/NCT07929571) — NOT_YET_RECRUITING · NCT07929571
- [GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial](https://clinicaltrials.gov/study/NCT06162715) — ACTIVE_NOT_RECRUITING · PHASE2, PHASE3 · NCT06162715
- [The Impact of Incretins on Fat-free Mass, Muscle Strength and Functional Capacity](https://clinicaltrials.gov/study/NCT07929831) — RECRUITING · NCT07929831
- [24-hour Clear Liquid Diet vs. Standard Fasting for Upper Gastrointestinal Endoscopy in Patients Taking Agonists of the GLP-1 Receptor](https://clinicaltrials.gov/study/NCT07929233) — NOT_YET_RECRUITING · NA · NCT07929233
- [Ocular Changes in Patients Using Tirzepatide or Semaglutide](https://clinicaltrials.gov/study/NCT07924618) — RECRUITING · NCT07924618
- [Exercise and Protein to Reduce Muscle Loss During GLP-1-Based Treatment in Type 2 Diabetes](https://clinicaltrials.gov/study/NCT07926152) — NOT_YET_RECRUITING · NA · NCT07926152

---

Source: AmericanPeptide.com — https://americanpeptide.com/catalog/tirzepatide
Data license: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Attribution: AmericanPeptide.com.
Research reference only — computational and educational content, not medical advice.